Influence of Simulated Gastrointestinal Fluids on Polymorphic Behavior of Anhydrous Carbamazepine Form III and Biopharmaceutical Relevance

References

1. 1.↵
   1. Amidon G.,
   2. Lennernas H.,
   3. Shah V. P.

   A theortical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12 ( 3), 413– 420.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Bertilsson L.

   Clinical pharmacokinetics of carbamazepine. Clin. Pharmacokinet. 1978, 3 ( 2), 128– 143.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Carino S. R.,
   2. Sperry D. C.,
   3. Hawley M.

   Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model. J. Pharm. Sci. 2006, 95 ( 1), 116– 125.

   OpenUrlPubMed
4. 4.↵
   1. Lang M.,
   2. Kampf J. W.,
   3. Matzger A. J.

   Form IV of carbamazepine. J. Pharm. Sci. 2002, 91 ( 4), 1186– 1190.

   OpenUrlPubMed
5. 5.↵
   1. Qu H.,
   2. Louhi-Kultanen M.,
   3. Kallas J.

   Solubility and stability of anhydrate/hydrate in solvent mixtures. Int. J. Pharm. 2006, 321 ( 1–2), 101– 107.

   OpenUrlPubMed
6. 6.↵
   1. Vishweshwar P.,
   2. McMahon J. A.,
   3. Bis J. A.,
   4. Zaworotko M. J.

   Pharmaceutical co-crystals. J. Pharm. Sci. 2006, 95 ( 3), 499– 516.

   OpenUrlPubMed
7. 7.↵
   1. Hassan Y.,
   2. Enein A.,
   3. Albadr A. A.

   Analytical Profile of Drug Substances, 3rd ed.; Academic Press: San Diego, CA, 2005; pp 87– 106.
8. 8.↵
   1. Young W. W. L.,
   2. Suryanarayanan R.

   Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions. J. Pharm. Sci. 1991, 80 ( 5), 496– 500.

   OpenUrlPubMed
9. 9.↵
   1. Meyer M. C.,
   2. Straughn A. B.,
   3. Jarivi E. J.,
   4. Woods G. C.,
   5. Pelsor F. R.,
   6. Shah V. P.

   The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 1992, 9 ( 12), 1612– 1616.

   OpenUrlPubMed
10. 10.↵
    1. Salameh A. K.,
    2. Taylor L. S.

    Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J. Pharm., Sci. 2006, 95 ( 2), 446– 461.

    OpenUrlPubMed
11. 11.↵
    1. Kaneniwa N.,
    2. Ichikawa J. I.,
    3. Yamaguchi T.,
    4. Hayashi K.,
    5. Watari N.,
    6. Sumi M.

    Dissolution behavior of carbamazepine polymorphs. Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan) 1987, 107 ( 10), 808– 813.

    OpenUrlPubMed
12. 12.↵
    1. Yumiko K.,
    2. Shusei I.,
    3. Shigeru I.

    Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 2000, 193 ( 2), 137– 146.

    OpenUrlPubMed
13. 13.↵
    1. McMahon L. E.,
    2. Timmins P.,
    3. Williams A. C.,
    4. York P.

    Characterization of dihydrates prepared from carbamazepine polymorphs. J. Pharm. Sci. 1996, 85 ( 10), 1064– 1069.

    OpenUrlPubMed
14. 14.↵
    1. Bhise S. B.,
    2. Rajkumar M.

    Effect of HPMC on solubility and dissolution of carbamazepine form III in simulated gastrointestinal fluids. A. J. Pharm. 2007, 2 ( 1), 235– 240.

    OpenUrl
15. 15.↵
    1. Rodriguez-Hornedo N.,
    2. Murphy D.

    Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci. 2004, 93 ( 2), 449– 460.

    OpenUrlPubMed
16. 16.↵
    1. Rodriguez-Hornedo N.,
    2. Murphy D.

    Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 1999, 88 ( 7), 651– 660.

    OpenUrlPubMed
17. 17.↵
    1. Crison J. R.,
    2. Weiner N. D.,
    3. Amidon G. L.

    Dissolution media for in vitro testing of water-insoluble drugs: Effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J. Pharm. Sci. 1997, 86 ( 3), 384– 388.

    OpenUrlPubMed
18. 18.↵
    1. Katzhendler I.,
    2. Azoury R.,
    3. Friedman M.

    Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methyl cellulose. J. Controlled Release 1998, 54 ( 1), 69– 85.

    OpenUrlPubMed
19. 19.↵
    1. Crison J. R.,
    2. Shah V. P.,
    3. Skelly J. P.,
    4. Amidon G. L.

    Drug dissolution into micellar solutions: Development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J. Pharm. Sci. 1996, 85 ( 9), 1005– 1011.

    OpenUrlPubMed
20. 20.↵
    1. Gu C. H.,
    2. Grant D. J. W.

    Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J. Pharm. Sci. 2001, 90 ( 9), 1277– 1287.

    OpenUrlPubMed
21. 21.↵
    1. Rustichelli C.,
    2. Gamberini G.,
    3. Ferioli V.,
    4. Gamberini M. C.,
    5. Ficarra R.,
    6. Tommasini S.

    Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biol. Anal. 2000, 23 ( 1), 41– 54.

    OpenUrl
22. 22.↵
    1. Dressman J.,
    2. Johannes K.

    Pharmaceutical Dissolution Testing, 1st ed.; Taylor and Francis: Boca Raton, FL, 2005; p 206.
23. 23.↵
    1. Zingone G.,
    2. Rubessa F.

    Release carbamazepine from polyvinyl pyrrolidine/vinyl acetate (PVA/VA) copolymer. STP Pharma. Sci. 1994, 4 ( 2), 122– 127.

    OpenUrl
24. 24.↵
    1. Luhtala S.

    Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm Nord. 1992, 4 ( 2), 85– 90.

    OpenUrl
25. 25.↵
    1. Luhtala S.,
    2. Kinos E.,
    3. Yliruusi J.,
    4. Tanninen V. P.

    X-ray powder diffraction study of carbamazepine crystals grown in surfactant solutions. Acta Pharm Nord. 1992, 4 ( 4), 283– 290.

    OpenUrl
26. 26.↵
    1. Ono M.,
    2. Tozuka Y.,
    3. Oguchi T.,
    4. Yamamura S.,
    5. Yamamoto K.

    Effects of dehydration temperature on water vapor adsorption and dissolution behavior of carbamazepine. Int. J. Pharm. 2002, 239 ( 1–2), 1– 12.

    OpenUrlPubMed
27. 27.↵
    1. Murphy D.,
    2. Rodriguez-Cintrin F.,
    3. Langevin B.,
    4. Kelly R. C.,
    5. Rodriguez-Hornedo N.

    Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J. Pharm. 2002, 246 ( 1–2), 121– 134.

    OpenUrlPubMed